Trial Profile

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 May 2022 According to a ChemoCentryx media release, data from this trial will be presented at the European Society for Pediatric Nephrology (ESPN), 2022.
05 May 2022 According to a ChemoCentryx media release, the company plans meeting with the FDA during the second half of the year to discuss the dataset from the ACCOLADE Phase II clinical trial.
01 Mar 2022 According to a ChemoCentryx media release, the company plans meeting with the FDA in 2022 to discuss the dataset from this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com